http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5280075-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
| filingDate | 2001-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36693e22b6e76c4fe705e3990eb34803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d4c4f85844b87cae9dd650a3b98145e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8576373aa5c64c6281d89ce7c6a5ac44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84abc477f88992602a4ad3ac5697a0e0 |
| publicationDate | 2003-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-5280075-A1 |
| titleOfInvention | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY |
| abstract | A pharmaceutical composition comprising as a first active agent, an estrogen (or natural or synthetic derivative thereof) in amounts sufficient to treat diseases, disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active agent, 6β, 7ß, 15ß, 16ß-dimethylene-3-oxo-17a-preg-4-eno-27.17-carbolactone (drospirenone) in amounts sufficient to protect the endometrium from the adverse effects of estrogen, together with a pharmaceutically acceptable carrier or excipient . A pharmaceutical composition comprising estradiol as a first active agent in amounts corresponding to a daily dose of 1 to 3 mg to treat diseases, disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active agent 6ß, 7ß , 15ß, 16ß-dimethylene-3-oxo-17a-preg-4-eno-27.17-carbolactone (drospirerona) in sufficient amounts corresponding to a daily dose of 1 to 3.5 mg to protect the endometrium from effects adverse effects of the estrogen, together with a pharmaceutically acceptable carrier or excipient. A multi-phase pharmaceutical preparation consisting of a number of separately dosed and individually removable daily dosage units disposed within a container unit intended for oral administration during a period of at least minus 21 days where said daily dosage units comprise a combination of estradiol in an amount in the range of from apr approximately 0.1 to 5 mg and drospirenone in the range of from about 0.25 to 6 mg. |
| priorityDate | 2000-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 17.